Nanobiotix (NBTX) Stock Forecast, Price Target & Predictions
NBTX Stock Forecast
Nanobiotix stock forecast is as follows: an average price target of $12.00 (represents a 217.46% upside from NBTX’s last price of $3.78) and a rating consensus of 'Buy', based on 1 wall street analysts offering a 1-year stock forecast.
NBTX Price Target
The average price target for Nanobiotix (NBTX) is $12.00 based on 1-year price targets from 1 Wall Street analysts in the past 3 months, with a price target range of $12.00 to $12.00. This represents a potential 217.46% upside from NBTX's last price of $3.78.
NBTX Analyst Ratings
According to 1 Wall Street analysts, Nanobiotix's rating consensus is 'Buy'. The analyst rating breakdown for NBTX stock is 0 'Strong Buy' (0.00%), 1 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Nanobiotix Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Aug 27, 2024 | Michael Schmidt | Guggenheim | $12.00 | $5.13 | 133.92% | 217.46% |
The latest Nanobiotix stock forecast, released on Aug 27, 2024 by Michael Schmidt from Guggenheim, set a price target of $12.00, which represents a 133.92% increase from the stock price at the time of the forecast ($5.13), and a 217.46% increase from NBTX last price ($3.78).
Nanobiotix Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | 1 | 1 |
| Avg Price Target | - | $12.00 | $12.00 |
| Last Closing Price | $3.78 | $3.78 | $3.78 |
| Upside/Downside | -100.00% | 217.46% | 217.46% |
In the current month, the average price target of Nanobiotix stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Nanobiotix's last price of $3.78. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Aug 27, 2024 | Guggenheim | - | Buy | Initialise |
Nanobiotix's last stock rating was published by Guggenheim on Aug 27, 2024. The company Initialise its NBTX rating from "null" to "Buy".
Nanobiotix Financial Forecast
Nanobiotix Revenue Forecast
| Jun 24 | |
|---|---|
| Revenue | - |
| Avg Forecast | $23.27M |
| High Forecast | $23.27M |
| Low Forecast | $23.27M |
| # Analysts | 1 |
| Surprise % | - |
Nanobiotix's average Quarter revenue forecast for undefined based on undefined analysts is $NaN, with a low forecast of $NaN, and a high forecast of $NaN. NBTX's average Quarter revenue forecast represents a NaN% decrease compared to the company's last Quarter revenue of $NaN (undefined).
Nanobiotix EBITDA Forecast
| Jun 24 | |
|---|---|
| # Analysts | 1 |
| EBITDA | - |
| Avg Forecast | $-22.28M |
| High Forecast | $-22.28M |
| Low Forecast | $-22.28M |
| Surprise % | - |
undefined analysts predict NBTX's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Nanobiotix's previous annual EBITDA (undefined) of $NaN.
Nanobiotix Net Income Forecast
| Jun 24 | |
|---|---|
| # Analysts | 1 |
| Net Income | - |
| Avg Forecast | $-10.71M |
| High Forecast | $-10.71M |
| Low Forecast | $-10.71M |
| Surprise % | - |
Nanobiotix's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. NBTX's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
Nanobiotix SG&A Forecast
| Jun 24 | |
|---|---|
| # Analysts | 1 |
| SG&A | - |
| Avg Forecast | $11.67B |
| High Forecast | $11.67B |
| Low Forecast | $11.67B |
| Surprise % | - |
Nanobiotix's average Quarter SG&A projection for undefined is $NaN, based on undefined Wall Street analysts, with a range of $NaN to $NaN. The forecast indicates a NaN% fall compared to NBTX last annual SG&A of $NaN (undefined).
Nanobiotix EPS Forecast
| Jun 24 | |
|---|---|
| # Analysts | 1 |
| EPS | - |
| Avg Forecast | $-0.23 |
| High Forecast | $-0.23 |
| Low Forecast | $-0.23 |
| Surprise % | - |
According to undefined Wall Street analysts, Nanobiotix's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to NBTX previous annual EPS of $NaN (undefined).
Nanobiotix Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| HEPA | Hepion Pharmaceuticals | $0.69 | $70.00 | 10044.93% | Buy |
| INAB | IN8bio | $0.32 | $14.00 | 4275.00% | Buy |
| DRMA | Dermata Therapeutics | $1.08 | $6.00 | 455.56% | Buy |
| IMMX | Immix Biopharma | $1.70 | $7.00 | 311.76% | Buy |
| CUE | Cue Biopharma | $1.08 | $4.33 | 300.93% | Buy |
| CNSP | CNS Pharmaceuticals | $0.13 | $0.50 | 284.62% | - |
| NBTX | Nanobiotix | $3.78 | $12.00 | 217.46% | Buy |
| ZURA | Zura Bio | $3.15 | $10.00 | 217.46% | Buy |
| TCRX | TScan Therapeutics | $4.21 | $12.00 | 185.04% | Buy |
| ANNX | Annexon | $5.46 | $14.00 | 156.41% | Buy |
| WVE | Wave Life Sciences | $14.21 | $22.14 | 55.81% | Buy |
| VECT | VectivBio | $16.87 | $18.00 | 6.70% | Buy |
| EFTR | eFFECTOR Therapeutics | - | $5.50 | - | Buy |
| PALI | Palisade Bio | $2.43 | $1.50 | -38.27% | Buy |